Physician profile
Darrell S Parsons
NPI 1144212440
$7,893.88
in general payments reported to CMS, 2019-2025
34 companies · $1,390 in 2025
The $1,390 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $1,108 · 2021: $863 · 2022: $1,711 · 2023: $1,288 · 2024: $739 · 2025: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,416.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,153.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,113.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $880.83 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Astrazeneca Pharmaceuticals LP | $880.40 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $411.23 | 2019-2025 | Evenity, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $374.02 | 2019-2023 | |
| Abbvie INC. | $345.04 | 2021-2025 | |
| Pfizer INC. | $310.92 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.27 | 2020-2024 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $216.57 | 2019-2022 | |
| Medtronic, INC. | $136.40 | 2022 | |
| Calliditas Therapeutics US INC. | $125.00 | 2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $124.16 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $78.10 | 2019-2022 | |
| Vifor Pharma, INC. | $67.97 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $54.14 | 2023 | |
| Exact Sciences Corporation | $53.31 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $39.90 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.31 | 2025 | Eliquis |
| Harmony Biosciences LLC | $22.93 | 2022 | |
| Insulet Corporation | $21.96 | 2023 | Omnipod |
| Biohaven Pharmaceutical Holding Company LTD. | $21.70 | 2022 | |
| Dexcom, INC. | $19.09 | 2022 | |
| Arbor Pharmaceuticals, INC. | $17.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.84 | 2021 | |
| Radius Health, INC. | $16.46 | 2020 | |
| Philips North America LLC | $16.23 | 2020 | |
| Gilead Sciences, INC. | $15.83 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.34 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.01 | 2020 | |
| Foundation Fusion Solutions, LLC | $13.47 | 2023 | |
| Zyla Life Sciences, INC. | $13.00 | 2020 | |
| Allergan, INC. | $12.37 | 2020 | |
| Xeris Pharmaceuticals, INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrell Parsons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.